Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors

Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors

The objective response rate (ORR) of tyrosine kinase inhibitors (TKIs) therapy in metastatic renal cell cancer (mRCC) patients was not satisfactory. Effective indicator of mRCC patient selection for TKI therapy is urgently needed. The function of tumor infiltrating B lymphocytes (TIBs) in tumor immu...

Full description

Bibliographic Details
Main Authors: Zhiyuan Lin, Li Liu, Yu Xia, Xiang Chen, Ying Xiong, Yang Qu, Jiajun Wang, Qi Bai, Jianming Guo, Jiejie Xu
Format: Article
Language:English
Published: Taylor & Francis Group 2018-10-01
Series:OncoImmunology
Subjects:
tumor infiltrating b lymphocyte
renal cell carcinoma
tyrosine kinase inhibitor
biomarkers
survival
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1477461

Internet

http://dx.doi.org/10.1080/2162402X.2018.1477461

Similar Items